摘要
背景:镧(La)被认为是非必需元素。 La在中国已经使用了几十年来提高了植物生产的产量,并且已经显示出在畜牧业饲养试验中有显着的性能增强效果。估计人类摄入La的量低于150μg,低于安全和可接受的每日摄入量估计限度的10%。 方法:本综述基于可用数据库中的文献检索。 结果:摄入La作为碳酸盐后,镧离子(La3 +)释放到胃中,并将磷酸盐中的磷酸盐复合物作为膳食磷酸盐,从而抑制磷酸盐的吸收。碳酸镧作为降低终末期肾衰竭血清磷酸盐的药物,于2004年被美国FDA和欧盟批准用于人类使用。当用于治疗晚期肾功能不全的患者时,碳酸镧以一定剂量口服给药最多每天3000毫克。镧离子从肠道吸收到循环是可以忽略的。尽管使用碳酸镧作为磷酸盐结合药物,但是可能会出现胃肠不适,伴有疼痛,呕吐和腹泻,并且没有记录全身性副作用。碳酸镧可能与具有阴离子基团的药物螯合,并且与碳酸镧治疗共同施用可能降低药物如四环素,喹诺酮和左旋甲状腺素的生物利用度。 结论:本评价结果证实碳酸镧是临床上有用的磷酸盐结合药物,对晚期肾功能衰竭的副作用很小。
关键词: 镧,镧系元素,稀土元素,晚期肾病,磷酸盐,甲状旁腺功能亢进,有毒作用。
Current Medicinal Chemistry
Title:Lanthanum Carbonate - A New Phosphate Binding Drug in Advanced Renal Failure
Volume: 25 Issue: 1
关键词: 镧,镧系元素,稀土元素,晚期肾病,磷酸盐,甲状旁腺功能亢进,有毒作用。
摘要: Background: Lanthanum (La) is considered to be a non-essential element. La has been used for several decades in China to improve yield in plant production and has also been shown to have significant performance enhancing effects in feeding trials on animal husbandry. The estimated dietary intake of La in humans is below 150 µg, which is lower than 10% of the estimated limit of safe and acceptable daily intake.
Methods: The present review is based on literature search in available databases.
Results: Upon ingestion of La as carbonate, the lanthanum ion (La3+) is released in the stomach and traps dietary phosphate as insoluble lanthanum phosphate complexes in the gut, thereby inhibiting phosphate absorption. Lanthanum carbonate as a drug to lower serum phosphate in endstage kidney failure was approved for human use by the US FDA in 2004 and by the EU in 2006. When used to treat patients with advanced renal insufficiency, lanthanum carbonate is administered orally at a dose of maximally 3000 mg per day. The uptake of lanthanum ions from the gut to the circulation is negligible. And few systemic side effects have been recorded upon the use of lanthanum carbonate as a phosphate binding drug, although gastrointestinal discomfort with pain, vomiting and diarrhea may occur. Lanthanum carbonate has the potential to chelate to drugs with anionic groups and therapeutic co-administration with lanthanum carbonate may reduce the bioavailibility of drugs like tetracyclines, quinolones and levothyroxine.
Conclusion: The findings in this review confirm that lanthanum carbonate is a clinically useful phosphate binding drug with few side effects in advanced renal failure.
Export Options
About this article
Cite this article as:
Lanthanum Carbonate - A New Phosphate Binding Drug in Advanced Renal Failure, Current Medicinal Chemistry 2018; 25 (1) . https://dx.doi.org/10.2174/0929867324666170509125840
DOI https://dx.doi.org/10.2174/0929867324666170509125840 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Design, Synthesis and Structure-Activity Relationship Studies of Novel 4 (1-adamantyl) Phenyl Analogues as HIF-1α Inhibitors
Medicinal Chemistry Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism True Antisense Oligonucleotides with Modified Nucleotides Restricted in the Nconformation
Current Topics in Medicinal Chemistry Patent Selections:
Recent Patents on Nanomedicine Relevance of Aromatase Inhibitors in Breast Cancer Treatment
Current Topics in Medicinal Chemistry Methylenetetrahydrofolate Reductase (MTHFR): A Novel Target for Cancer Therapy
Current Pharmaceutical Design Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery
Current Vascular Pharmacology A Stereospecific Route for the Preparation of Trans-Combretastatin Analogs: Synthesis and Cytotoxicity
Letters in Drug Design & Discovery Protease-Activated Receptors (PARs) are Partly Pro-Inflammatory and Partly Anti-Inflammatory: Will PAR Agonists or Antagonists Participate in Future Drug Therapies?
Current Drug Targets Chemical and Pharmacological Significance of Natural Guanidines from Marine Invertebrates
Mini-Reviews in Medicinal Chemistry Airway Fibrosis and Angiogenesis due to Eosinophil Trafficking in Chronic Asthma
Current Molecular Medicine The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas
Current Drug Targets rDNA Mediated Bioconjugates: Fusion Proteins and their Intended Use in Medicine
Current Topics in Medicinal Chemistry An Overview of the Current and Novel Drugs for Alzheimers Disease with Particular Reference to Anti-Cholinesterase Compounds
Current Pharmaceutical Design Nucleic Acids as Therapeutic Agents
Current Topics in Medicinal Chemistry Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Current Signal Transduction Therapy Radiation Therapy in the Early 21st Century: Technological Advances
Current Cancer Therapy Reviews Management of Food-Induced Anaphylaxis: Unsolved Challenges
Current Clinical Pharmacology Angiotensin II, Cell Proliferation and Angiogenesis Regulator: Biologic and Therapeutic Implications in Cancer
Current Vascular Pharmacology